Sequence: YGRKKRRQRRR (Tat 47–57, as purchased)
| Experiment Id | EXP001691 |
|---|---|
| Paper | Liquid Crystalline Nanodispersions Functionalized with Cell-Penetrating Peptides for Topical Deliver |
| Peptide | TAT (HIV-1 Tat 47–57) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | 0.1 mM (final) for formulations |
| Rna Concentration | 10 µM siRNA in formulations/solutions |
| Mixing Ratio | CPP pre-complexed with siRNA 30 min, then incorporated into nanodispersion; (molar ratio ~10:1 CPP:siRNA) |
| Formulation Format | Hexagonal liquid crystalline nanodispersion (monoolein/oleic acid) with PEI, functionalized with CPP |
| Formulation Components | MO:OA:PEI:aqueous phase (8:2:1:89, w/w/w/w) + Poloxamer 407 (1.5%) in Tris-HCl pH 6.5; PEI 25 kDa; + TAT + siRNA |
| Size Nm | 310.00 |
| Zeta Mv | 11.90 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | L929 fibroblasts (24 h uptake study by flow cytometry and fluorescence microscopy) |
| Animal Model | |
| Administration Route | |
| Output Type | uptake (flow cytometry + fluorescence microscopy) |
| Output Value | ~90% FAM-positive cells for MO:OA:PEI nanodispersions; TAT functionalization increased fluorescence intensity vs no-CPP and vs PNT. |
| Output Units | |
| Output Notes | Uptake measured after 24 h incubation in serum-free medium; samples diluted 1:50 in PBS before addition. |
| Toxicity Notes | MO:OA:PEI nanodispersions showed no significant cytotoxicity vs untreated L929; PEI-only and OAM controls were more toxic. |
| Curation Notes |